Bormioli Pharma has opened a glass research centre at the headquarters of the Institute of Materials for Electronics and Magnetism - National Research Council.
The health emergency due to the COVID-19 pandemic and the subsequent search for a vaccine have further highlighted the importance of glass containers in the drug supply chain, the company points out, both from the point of view of performance and compatibility with formulations.
In the laboratories, Bormioli will conduct analyses on the chemico-physical characteristics of its glass bottles and will promote research programs to identify alternative formulations and surface treatments.
"With this project, we aim to create a centre of excellence for innovation in glass containers for drugs with high therapeutic value", said Andrea Lodetti, CEO of Bormioli Pharma. "We will thus be able to reverse the paradigm in which the packaging supplier intervenes only at the end of the development process of new formulations, providing our contribution from the earliest stages of clinical trials".
In the coming months, Bormioli Pharma and CNR will also fund a PhD grant for the development of a glass bottles capable of offering “chemical neutrality, shock absorption and assembly line flow characteristics superior to any packaging solution on the market today”.
